Georges Gemayel appointed non-executive chairman of Enterome
pharmafile | September 29, 2015 | Appointment | Manufacturing and Production |
Drug and diagnostics development firm Enterome Bioscience SA has appointed Dr Georges Gemayel to the Enterome board as a non-executive chairman. He replaces Bernard Gilly, who becomes a non-executive director.
Dr Gemayel has over 25 years of experience in the pharma industry, including management and executive positions in the US, Europe and the Middle East. He currently serves on the board of directors of US publicly-traded companies Supernus Pharmaceuticals, Raptor Pharma, and Dimension Therapeutics.
He is the chairman of the boards of OxThera AB, and Orphazyme ApS. From 2008 to 2009, Dr Gemayel was president and chief executive officer of Altus Pharmaceuticals. From 2003 to 2008, he was executive vice president at Genzyme where he was responsible for the company’s global therapeutics, transplant, renal and biosurgery businesses.
From 1988 to 2003, he held progressively senior roles at Hoffmann La-Roche and Roche Labs, most recently as vice president, national specialty care, responsible for its US business in dermatology, oncology, transplantation, hepatitis and HIV.
Outgoing non-executive chairmain Bernard Gilly says: “We are very pleased to welcome Georges to the Enterome Board. He has a wealth of experience in the global pharma industry and particularly in the clinical and commercial development of innovative products and disease management solutions. We look forward to the valuable contributions that he will make to the further the growth and development of Enterome.”
Gemayel adds: “I am delighted to join Enterome at this exciting stage in its development, as it becomes poised to leverage its leadership in the understanding of the gut microbiome across drug discovery and diagnostics.”
